Promoter CpG island methylation markers in colorectal cancer: the road ahead

Muriel X. G. Draht; Robert G. Riedl; Hanneke Niessen; Beatriz Carvalho; Gerrit A. Meijer; James G. Herman; Manon van Engeland; Veerle Melotte; Kim M. Smits

doi:10.2217/EPI.12.9

Promoter CpG island methylation markers in colorectal cancer: the road ahead

Muriel X. G. Draht, Robert G. Riedl, Hanneke Niessen, Beatriz Carvalho, Gerrit A. Meijer, James G. Herman, Manon van Engeland, Veerle Melotte^*, Kim M. Smits

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Despite increasing knowledge on the biology, detection and treatment of colorectal cancer (CRC), the disease is still a major health problem. Hypermethylation of promoter regions of genes has been studied extensively as a contributor in CRC carcinogenesis. In addition, it is the topic of many studies focusing on biomarkers for the early detection, prediction of prognosis and treatment outcome. Methylation markers may be preferred over current screening and test methods as they are stable and easy to detect. However, almost no methylation marker is currently being used in clinical practice, often due to a lack of sensitivity, specificity, or validation of the results. This review summarizes the current knowledge of hypermethylation biomarkers for CRC detection, progression and treatment outcome.

Original language	English
Pages (from-to)	179-194
Journal	Epigenomics
Volume	4
Issue number	2
DOIs	https://doi.org/10.2217/EPI.12.9
Publication status	Published - Apr 2012

Keywords

colorectal cancer
DNA methylation
early detection marker
prediction marker
prognostic marker

Access to Document

10.2217/EPI.12.9

Cite this

@article{7d61e2a361cc433691ac9f01681a23bb,

title = "Promoter CpG island methylation markers in colorectal cancer: the road ahead",

abstract = "Despite increasing knowledge on the biology, detection and treatment of colorectal cancer (CRC), the disease is still a major health problem. Hypermethylation of promoter regions of genes has been studied extensively as a contributor in CRC carcinogenesis. In addition, it is the topic of many studies focusing on biomarkers for the early detection, prediction of prognosis and treatment outcome. Methylation markers may be preferred over current screening and test methods as they are stable and easy to detect. However, almost no methylation marker is currently being used in clinical practice, often due to a lack of sensitivity, specificity, or validation of the results. This review summarizes the current knowledge of hypermethylation biomarkers for CRC detection, progression and treatment outcome.",

keywords = "colorectal cancer, DNA methylation, early detection marker, prediction marker, prognostic marker",

author = "Draht, {Muriel X. G.} and Riedl, {Robert G.} and Hanneke Niessen and Beatriz Carvalho and Meijer, {Gerrit A.} and Herman, {James G.} and {van Engeland}, Manon and Veerle Melotte and Smits, {Kim M.}",

year = "2012",

month = apr,

doi = "10.2217/EPI.12.9",

language = "English",

volume = "4",

pages = "179--194",

journal = "Epigenomics",

issn = "1750-1911",

publisher = "Routledge/Taylor & Francis Group",

number = "2",

}

TY - JOUR

T1 - Promoter CpG island methylation markers in colorectal cancer: the road ahead

AU - Draht, Muriel X. G.

AU - Riedl, Robert G.

AU - Niessen, Hanneke

AU - Carvalho, Beatriz

AU - Meijer, Gerrit A.

AU - Herman, James G.

AU - van Engeland, Manon

AU - Melotte, Veerle

AU - Smits, Kim M.

PY - 2012/4

Y1 - 2012/4

N2 - Despite increasing knowledge on the biology, detection and treatment of colorectal cancer (CRC), the disease is still a major health problem. Hypermethylation of promoter regions of genes has been studied extensively as a contributor in CRC carcinogenesis. In addition, it is the topic of many studies focusing on biomarkers for the early detection, prediction of prognosis and treatment outcome. Methylation markers may be preferred over current screening and test methods as they are stable and easy to detect. However, almost no methylation marker is currently being used in clinical practice, often due to a lack of sensitivity, specificity, or validation of the results. This review summarizes the current knowledge of hypermethylation biomarkers for CRC detection, progression and treatment outcome.

AB - Despite increasing knowledge on the biology, detection and treatment of colorectal cancer (CRC), the disease is still a major health problem. Hypermethylation of promoter regions of genes has been studied extensively as a contributor in CRC carcinogenesis. In addition, it is the topic of many studies focusing on biomarkers for the early detection, prediction of prognosis and treatment outcome. Methylation markers may be preferred over current screening and test methods as they are stable and easy to detect. However, almost no methylation marker is currently being used in clinical practice, often due to a lack of sensitivity, specificity, or validation of the results. This review summarizes the current knowledge of hypermethylation biomarkers for CRC detection, progression and treatment outcome.

KW - colorectal cancer

KW - DNA methylation

KW - early detection marker

KW - prediction marker

KW - prognostic marker

U2 - 10.2217/EPI.12.9

DO - 10.2217/EPI.12.9

M3 - Article

SN - 1750-1911

VL - 4

SP - 179

EP - 194

JO - Epigenomics

JF - Epigenomics

IS - 2

ER -

Promoter CpG island methylation markers in colorectal cancer: the road ahead

Abstract

Keywords

Access to Document

Fingerprint

Cite this